Welcome to our dedicated page for PROKIDNEY SEC filings (Ticker: PROK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProKidney Corp. filings document a late clinical-stage biotechnology issuer focused on rilparencel, an autologous renal cell therapy candidate for chronic kidney disease in patients with diabetes. Recent Form 8-K reports furnish operating and financial results, Regulation FD investor presentations, clinical-study and development-plan updates, FDA-pathway disclosures, financial-position information, and material-event or material-agreement disclosures.
Proxy materials describe annual meeting proposals, board elections, auditor ratification, stockholder voting procedures, and governance matters for the public company.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed a Schedule 13G reporting beneficial ownership of 8,519,982 shares of ProKidney Corp. Class A common stock, representing 6.0% of the class as of December 31, 2025.
The filing shows no sole voting or dispositive power, with all reported voting and dispositive authority shared between these reporting persons, and certifies that the holdings are maintained in the ordinary course of business without the purpose of changing or influencing control of ProKidney.
ProKidney Corp. filed a current report to share an updated investor presentation that management plans to use in meetings with investors and analysts. The presentation, furnished as Exhibit 99.1 and on the company website, updates the Phase 3 REGEN-006 (PROACT 1) trial plan.
The PROACT 1 study now targets enrollment of approximately 470 subjects. ProKidney continues to expect topline data for the surrogate endpoint (eGFR slope) in the second quarter of 2027 and now anticipates topline data for the confirmatory composite time-to-event endpoint in the second half of 2029, with statistical powering assumptions unchanged.
ProKidney Corp. filed a current report to notify investors that it has updated its investor presentation. Senior management plans to use this updated presentation in meetings with investors and analysts, and it is available on the company’s website as well as attached as Exhibit 99.1. The company states that this material is being furnished under Regulation FD rather than filed, meaning it is not automatically part of other securities law filings unless specifically incorporated by reference. ProKidney also notes that providing this presentation does not represent a determination that the information is material or complete for investment decisions.
ProKidney Corp. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 to this report.
The information provided, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly stated.
ProKidney (PROK) reported Q3 2025 results with a net loss including noncontrolling interest of $35.8 million and a net loss available to Class A stockholders of $16.5 million, or $0.12 per share. Revenue was $217,000, reflecting leasing income from tenant agreements.
Operating expenses were $38.8 million, down from $49.0 million a year ago, as research and development totaled $26.8 million and general and administrative was $11.9 million. For the nine months, revenue reached $668,000 and operating loss was $119.6 million.
Liquidity consisted of $95.3 million in cash and cash equivalents and $176.4 million in marketable securities as of September 30, 2025. Net cash used in operating activities was $87.6 million for the nine months. The company sold 1,989,147 Class A shares under its 2025 at-the-market program for $7.1 million during the quarter and, after quarter-end, an additional 5,463,195 shares for $17.1 million in proceeds.
ProKidney completed a domestication to Delaware and related restructuring effective July 1, 2025; management states these transactions did not have a significant impact on the financial statements.
ProKidney Corp. filed Post-Effective Amendment No. 3 to its S-1 on Form S-3, adopting the prior registration after its Delaware domestication under Rule 414. The prospectus now covers up to 169,635,462 shares of Class A common stock for resale by selling securityholders, reflecting updated holder information and a reduction in the number of shares offered since the initial registration.
The company states it will not receive any proceeds from sales by the selling securityholders and will bear registration-related expenses other than underwriting discounts and commissions. No additional securities are being registered in this amendment. ProKidney’s Class A common stock trades on Nasdaq under “PROK.”
ProKidney Corp. entered into a material definitive agreement to sell its Greensboro, North Carolina real property to Northpoint Development, LLC for approximately $19.1 million in cash.
The new agreement, signed on October 17, 2025, follows the termination of a prior sale agreement with Williams Development Group. The Northpoint agreement includes customary representations and closing conditions. The company plans to file the full agreement as an exhibit to its Form 10-K for the year ended December 31, 2025.
ProKidney Corp. (Nasdaq: PROK) furnished a Current Report on Form 8-K stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1, and the filing also references an Inline XBRL cover page file for the report.
The report notes that the furnished press release and related information are not being "filed" for purposes of certain Exchange Act liabilities and will not be incorporated by reference into other registration statements unless expressly stated. The filing identifies ProKidney as an emerging growth company and is signed on behalf of the registrant by Chief Financial Officer James Coulston.
ProKidney Corp. reported a substantial operating loss as it advances its lead autologous cell therapy, rilparencel, through late-stage trials while funding clinical and manufacturing operations. For the six months ended June 30, 2025 the consolidated net loss before noncontrolling interest was $74.9 million, cash and cash equivalents were $84.9 million and marketable securities totaled $209.8 million, giving combined short-term liquidity of about $294.7 million. Total assets were $372.1 million and stockholders' deficit was $1.0025 billion, reflecting a large redeemable noncontrolling interest of $1.342 billion.
The company is progressing Phase 3 PROACT 1 to support accelerated approval of rilparencel: the FDA agreed that eGFR slope can serve as a surrogate endpoint for an accelerated BLA and specified an acceptable effect size of at least 1.5 mL/min/1.73m2/year. ProKidney completed the REGEN-007 Phase 2 trial showing in one dosing arm a statistically significant improvement in annual eGFR slope of 4.6 mL/min/1.73m2/year (p<0.001). The company has enrolled nearly half the patients required for the accelerated approval analysis, with topline eGFR slope readout anticipated in Q2 2027.